October 2020 PMID 32800508

NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.

Domingo Pascual-Figal, Rolf Wachter, Michele Senni, Weibin Bao, Adele Noè, Heike Schwende, Dmytro Butylin, Margaret F Prescott

Full text PDF Download social card

Mentions

Peak: 11 in Sep 2020

across 3 sources since Aug 2020

Extended reach

139,470

potential audience

Total likes

348

Video views

19,178

Mentions per month

Aug 2020 – Jan 2025

Where it's discussed

X / Twitter22 posts
YouTube4 videos
News2 articles

AI synopsis

What people are saying

Discussions around the article include expressions of awareness and acknowledgment of its findings, such as mentions of 'response to sacubitrilvalsartan' and references to the TRANSITION study. The tone is generally neutral or slightly positive, with some posts emphasizing the potential clinical relevance but not indicating a definitive paradigm shift.

AgreementNeither agree nor disagree

The discussions show a mix of support and skepticism, with some posts acknowledging the findings while others question the clinical significance.

InterestModerate interest

Overall interest is moderate, as posts mention the study and its implications but do not dive deeply into detailed methodology or results.

EngagementModerate engagement

Posts reflect some engagement through sharing summaries and expressing opinions, but there is limited active debate or detailed analysis.

ImpactNeutral impact

The impact appears moderate; the discussion highlights the relevance of NT-proBNP response but lacks evidence of broad clinical practice changes or high-impact assertions.

Abstract in brief

This study investigated how the medication sacubitrilvalsartan affects NTproBNP levels in patients hospitalized with heart failure and reduced ejection fraction, focusing on factors linked to significant reductions in NTproBNP.
Patients who started sacubitrilvalsartan while still in the hospital showed a greater initial decrease in NTproBNP and higher rates of favorable response compared to those who started after discharge; however, reductions over time were similar between groups.
A significant decline in NTproBNP at 4 weeks was associated with a lower risk of future heart failure hospitalizations or cardiovascular death within 26 weeks, and factors like higher initial doses and baseline NTproBNP levels predicted better treatment response.

Read the full abstract

All mentions

Guidelines for Pharmacotherapy in Heart Failure Management

Learn about the optimal medication prescriptions for patients with HFrEF based on the 2021 ESC Guidelines. This video discusses vericiguat, a promising new medication shown to reduce cardiovascular events in high-risk…

CardioMinds, Dr. Sherif Altoukhy · Jun 12, 2022 9,384 views

Understanding the Prescribing Guidelines for ARNI in Heart Failure Management

This video discusses the benefits, tips, and guidelines for prescribing ARNI (Angiotensin Receptor-Neprilysin Inhibitor) for heart failure patients, based on the 2021 ESC guidelines and recent clinical trials like…

CardioMinds, Dr. Sherif Altoukhy · Jul 31, 2022 4,847 views

Understanding ESC Guidelines for Prescribing ARNI in Heart Failure

A revolutionary medication for HF patients that needs understanding of its benefits beside its tips and tricks when you prescribe it. This highlights the 2021 ESC Guidelines for treating acute and chronic heart failure…

CardioMinds, Dr. Sherif Altoukhy · Jul 30, 2022 3,027 views

Optimizing Pharmacotherapy for Heart Failure with Reduced Ejection Fraction

This video explores the optimal medication strategies for patients with heart failure and reduced ejection fraction, in accordance with the 2021 ESC Guidelines. It examines the efficacy of new treatments, including…

CardioMinds, Dr. Sherif Altoukhy · Jun 11, 2022 1,920 views

Chiro

@Chiro23803850 · X

RT @KagawaECG: ARNIのレスポンダーのまとめ論文「2週間後のNTproBNPの低下具合で1年後の効き目が予測できうる心不全薬」というニュアンスのことを山下先生がおっしゃっていて，とても勉強になりました _φ(･_･ https://t.co/zP9mGa…

Jan 25, 2025 · 2 shares · 223 followers View post →

Dr.トモ＠心電図オタク

@ecgotaku · X

Jul 20, 2024 · 2 shares · 1,298 followers View post →

KagawaECG

@KagawaECG · X

Jul 19, 2024 · 10 likes · 2 shares · 12,013 followers View post →

Ana Ayestarán

@AnaAyestaran · X

RT @petita_libelula: NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRAN…

Oct 24, 2020 · 2 shares · 289 followers View post →

Sara Ortonobes

@petita_libelula · X

NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study https://t.co/h1xGdbxaY2

Oct 23, 2020 · 1 like · 2 shares · 387 followers View post →

Mahek Shah, MD

@Cardiobro · X